AFTER-CLOSE BIOTECH TRIAGE · JAPAN
Know which disclosures deserve your diligence queue.
A small, source-linked English digest of clinical, regulatory, deal, and financing updates from five Japan-listed biotech companies.
No card. One email. It stops automatically.
PUBLIC PREVIEW
The latest three signals
Loading official sources…
TRY THE ACTUAL OUTPUT
Get the full seven-day digest once.
See the exact email a subscriber receives. Your address is used for this delivery only; the sample does not start a recurring list.
PAID AUTOMATION
Stop checking five IR pages.
One concise email after the Japanese market close on weekdays. Cancel in Stripe’s self-serve portal.
- Source-linked supported signals from the covered companies
- Original headline and official source link
- Explicit notice when source coverage is partial
EXPLICIT COVERAGE
Five companies, not the whole market.
Chordia Therapeutics (190A), StemRIM (4599), Modalis Therapeutics (4883), Heartseed (219A), and Delta-Fly Pharma (4598).
This is a disclosure-triage product, not a complete archive, translation service, or investment recommendation. Always review the linked official source.